New Name Reflects Strategic Approach

Nimbus Biotechnologie, (Leipzig, Germany) a supplier of ADME-Tox products and services, has changed its name to Sovicell GmbH, reflecting
the company’s move to become a full range, international supplier of ADME-Tox products and services for pre-clinical research..
Commenting on the name change Dr Hinnerk Boriss, CEO said: “This name change supports our company’s commercial development and more accurately reflects our new positioning. We are continually enhancing our ADME-Tox product portfolio and services to meet our pharmaceutical and biotechnology customers’ needs and look forward to continuing to work with our supportive existing partners as well as expanding our client base internationally.”
Founded in 1994, Sovicell (formerly Nimbus) has developed its proprietary TRANSIL® bead-based in vitro testing procedures for measuring a drug candidate’s membrane permeability and protein binding. The company also provides cryopreserved hepatocytes exclusively for
Cytonet and a blood-to-brain adsorption kit based on natural biological membranes to aid in the development of CNS drugs.
To facilitate continued expansion the company recently moved premises in Leipzig’s BioCity.